In Brief: Toxikon
This article was originally published in The Gray Sheet
Executive Summary
Toxikon: FDA tells environmental sciences and toxicology testing firm that its response to an April 10 agency warning letter ("The Gray Sheet" May 1, I&W-11) satisfactorily addresses all issues raised by the agency. In a May 4 letter, FDA says that the information provided by the company in an April 12 correspondence "satisf[ies] our concerns expressed in the warning letter." Toxikon reports that "no corrective actions were required"...
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.